Lilly Medical Company

Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.

Investopedia on MSN · 1d

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report.

Reuters on MSN · 1d

Lilly forecasts weak sales of weight-loss drug in fourth quarter

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.

MarketWatch on MSN · 1d

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

Quartz on MSN · 1d

Eli Lilly was hoping weight loss drug demand would be even bigger

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.

Hosted on MSN3d

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

BioPharma Dive1d

Lilly blames slower-than-expected growth for 2024 sales miss

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Reuters3d

Lilly sues two medical spas over copycat weight-loss drugs

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

11d

Prediction: These 3 Healthcare Stocks Will Soar in 2025

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Nasdaq20d

Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.

Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up. I think Lilly is a no-brainer opportunity for investors with a ...

6don MSN

Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Reuters2d

Eli Lilly and Co

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities might be on hot button ...

Investopedia23d

Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea

Eli Lilly shares were up 1.6% at midday Monday, having gained about 34% on the year. Shares of ResMed (RMD), a medical device company that makes much of its revenue through the sale of sleep ...

Ibj.com5d

Q&A with Kristin Sherman: Life sciences veteran is fighting for women’s health

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results